zoledronic acid

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bone Metastases

Conditions

Bone Metastases, Breast Cancer, Lung Cancer, Prostate Cancer

Trial Timeline

Dec 1, 2005 → Mar 1, 2007

NCT ID

NCT00264420

About zoledronic acid

zoledronic acid is a phase 1 stage product being developed by Novartis for Bone Metastases. The current trial status is completed. This product is registered under clinical trial identifier NCT00264420. Target conditions include Bone Metastases, Breast Cancer, Lung Cancer.

What happened to similar drugs?

16 of 20 similar drugs in Bone Metastases were approved

Approved (16) Terminated (1) Active (4)

✅Reclast (ZOL446, zoledronic acid)NovartisApproved

✅zoledronic acidNovartisApproved

✅Zoledronic acidNovartisApproved

✅Disodium pamidronate + PlaceboNovartisApproved

✅Zoledronic acidNovartisApproved

✅PamidronateNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01197300	Phase 3	Completed	Oct 25, 2010	Feb 27, 2019	Osteoporosis
NCT01087008	Approved	Completed	Apr 1, 2010	Jun 5, 2013	Multiple Myeloma
NCT01004510	Phase 2	Terminated	Nov 1, 2009	Apr 1, 2011	Malignant Pleural Effusion
NCT00909961	Phase 3	Completed	Nov 1, 2009	Dec 16, 2011	Postmenopausal Osteoporosis
NCT00966992	Phase 2	Terminated	Aug 1, 2009	Mar 1, 2010	Uterine Cervical Neoplasms
NCT00760370	Phase 2	Completed	Dec 1, 2008	Dec 1, 2011	Multiple Myeloma
NCT00774020	Approved	Completed	Oct 30, 2008	Jan 14, 2011	Paget's Disease of Bone
NCT00740129	Approved	Completed	Oct 21, 2008	Mar 14, 2011	Paget's Disease of the Bone
NCT00745485	Approved	Completed	Aug 1, 2008	—	Osteoporosis
NCT00477217	Phase 2	Withdrawn	Jan 1, 2008	May 1, 2009	Osteonecrosis
NCT00622505	Approved	Completed	Nov 7, 2007	Apr 3, 2012	Multiple Myeloma
NCT00982124	Phase 3	Completed	Oct 1, 2007	Apr 1, 2016	Osteogenesis Imperfecta
NCT01218035	Approved	Completed	May 1, 2007	Jun 1, 2011	Hip Osteoarthritis
NCT00434447	Approved	Completed	Dec 1, 2006	—	Bone Neoplasms
NCT00424983	Phase 1	Completed	Nov 1, 2006	Nov 1, 2009	Multiple Myeloma
NCT00391950	Phase 3	Terminated	Oct 1, 2006	—	Prostate Cancer
NCT00361595	Pre-clinical	Completed	Aug 1, 2006	Apr 1, 2008	Osteoporosis
NCT00334139	Approved	Completed	May 1, 2006	Jul 1, 2009	Prostate Cancer
NCT00391690	Approved	Completed	Feb 1, 2006	—	Prostate Cancer
NCT00375427	Phase 3	Completed	Feb 1, 2006	—	Breast Cancer With Bone Metastasis

Competing Products

20 competing products in Bone Metastases

See all competitors

Product	Company	Stage	Hype Score
Denosumab + Zoledronic Acid	Daiichi Sankyo	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
Enzalutamide	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Merestinib	Eli Lilly	Phase 1	21
FORTEO + Placebo	Eli Lilly	Phase 1	29
Arzoxifene + Placebo	Eli Lilly	Phase 3	40
Tanezumab	Eli Lilly	Phase 3	40
Anastrozole + Tamoxifen	AstraZeneca	Phase 3	40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Zoledronic acid + Letrozole	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Nilotinib	Novartis	Phase 1	29
Reclast (ZOL446, zoledronic acid)	Novartis	Approved	43
Zoledronic acid	Novartis	Phase 3	32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid	Novartis	Phase 3	40
Ruxolitinib continuous therapy	Novartis	Phase 2	39
zoledronic acid	Novartis	Approved	43